Sangamo Therapeutics Inc (SGMO) Stake Increased by Dynamic Technology Lab Private Ltd

Share on StockTwits

Dynamic Technology Lab Private Ltd grew its holdings in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) by 171.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,384 shares of the biopharmaceutical company’s stock after acquiring an additional 25,483 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Sangamo Therapeutics were worth $573,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. Wells Fargo & Company MN raised its position in shares of Sangamo Therapeutics by 42.2% during the 2nd quarter. Wells Fargo & Company MN now owns 789,981 shares of the biopharmaceutical company’s stock valued at $11,218,000 after buying an additional 234,346 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in Sangamo Therapeutics by 14.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 565,601 shares of the biopharmaceutical company’s stock worth $8,032,000 after acquiring an additional 71,134 shares in the last quarter. Cubist Systematic Strategies LLC grew its stake in Sangamo Therapeutics by 193.6% in the 1st quarter. Cubist Systematic Strategies LLC now owns 65,087 shares of the biopharmaceutical company’s stock worth $1,237,000 after acquiring an additional 42,917 shares in the last quarter. Prudential Financial Inc. grew its stake in Sangamo Therapeutics by 331.9% in the 1st quarter. Prudential Financial Inc. now owns 505,536 shares of the biopharmaceutical company’s stock worth $9,605,000 after acquiring an additional 388,480 shares in the last quarter. Finally, Creative Planning grew its stake in Sangamo Therapeutics by 192.1% in the 2nd quarter. Creative Planning now owns 30,413 shares of the biopharmaceutical company’s stock worth $432,000 after acquiring an additional 20,000 shares in the last quarter. 63.84% of the stock is owned by hedge funds and other institutional investors.

SGMO stock opened at $14.22 on Tuesday. Sangamo Therapeutics Inc has a one year low of $11.30 and a one year high of $27.50. The firm has a market cap of $1.72 billion, a P/E ratio of -20.33 and a beta of 2.97. The company has a current ratio of 7.24, a quick ratio of 7.24 and a debt-to-equity ratio of 0.07.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.02). The company had revenue of $21.42 million during the quarter, compared to analyst estimates of $21.43 million. Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. The firm’s revenue for the quarter was up 159.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.17) EPS. Research analysts predict that Sangamo Therapeutics Inc will post -0.69 earnings per share for the current year.

In other Sangamo Therapeutics news, CFO Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $14.66, for a total transaction of $73,300.00. Following the transaction, the chief financial officer now directly owns 12,250 shares of the company’s stock, valued at $179,585. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director H Stewart Parker bought 2,000 shares of Sangamo Therapeutics stock in a transaction on Friday, September 7th. The shares were purchased at an average cost of $13.52 per share, for a total transaction of $27,040.00. The disclosure for this purchase can be found here. Over the last three months, insiders sold 25,000 shares of company stock worth $362,200. Insiders own 1.20% of the company’s stock.

A number of equities analysts have commented on SGMO shares. ValuEngine downgraded shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, September 6th. BidaskClub raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, September 5th. Cowen reissued a “buy” rating on shares of Sangamo Therapeutics in a research report on Monday, July 23rd. Bank of America initiated coverage on shares of Sangamo Therapeutics in a report on Wednesday, June 20th. They issued a “buy” rating and a $24.00 price target for the company. Finally, Wedbush reaffirmed a “hold” rating and issued a $9.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, July 24th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Sangamo Therapeutics presently has a consensus rating of “Buy” and an average target price of $21.00.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

See Also: Fundamental Analysis and Individual Investors

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.